Clinical trials: Atheroscleroses
Peripheral Arterial Disease
CVI Drug Coated Balloon First In Human Trial
The purpose of this study is to assess safety and the inhibition of restenosis of the CVI Paclitaxel-coated PTA Balloon Catheter in the treatment of de-novo occluded/stenotic or reoccluded/restenotic superficial femoral (SFA) or…
- Trial name
- NCT02110524
- Testing
- Percutaneous Transluminal Angioplasty
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Spectranetics Corporation
Infrainguinal Peripheral Artery Disease, Peripheral Arterial Disease
Post-Market Registry of AURYON Atherectomy Device in Subjects Affected With Infrainguinal Peripheral Artery Disease
The PATHFINDER Registry is a prospective, non-randomized, single arm, multicenter observational study. This pilot registry is aimed to evaluate the performance (peri-procedural) and clinical outcomes (intermediate and long-term)…
- Conditions
- Infrainguinal Peripheral Artery Disease, Peripheral Arterial Disease, PAD
- Trial name
- PATHFINDER (NCT04229563)
- Testing
- AURYON Atherectomy System
- Where
- 10 sites in United States
- Volunteers
- 102 people
- Sponsor
- Angiodynamics, Inc.
Critical Limb Ischemia, Buerger's Disease
Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease
The goal of this observational, practice-based feasibility study is to observe the efficacy and safety of intramuscular administration of Stempeucel® in Malaysian patients with critical limb ischemia (CLI) due to Buerger's…
- Trial name
- NCT05854615
- Testing
- Adult human bone marrow derived, cultured, pooled, allogeneic mesenchymal stromal cells
- Where
- Malaysia
- Volunteers
- 3 people
- Sponsor
- Cell Biopeutics Resources Sdn Bhd
Peripheral Artery Disease, Peripheral Vascular Disease
Absolute Pro® MOMENTUM™
To evaluate the safety and effectiveness of the Absolute Pro® Peripheral Self-Expanding Stent System and the Absolute Pro® LL Peripheral Self-Expanding Stent System for the treatment of subjects with atherosclerotic de novo or…
- Trial name
- MOMENTUM (NCT01444378)
- Testing
- Stenting using Absolute Pro® and Pro LL® Peripheral Stent Systems
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Multicentre Registry of CCTA, IVUS and OCT
The Invictus Registry will compare the diagnostic performance of coronary computed tomography angiography (CCTA) versus intravascular imaging by intravenous ultrasound (IVUS) or optical coherence tomography (OCT) for the…
- Trial name
- NCT04066062
- Where
- 9 sites in Japan
- Volunteers
- 1,700 people
- Sponsor
- Cleerly, Inc.
Peripheral Arterial Disease, Peripheral Vascular Diseases
Real-World Registry Assessing the Clinical Use of the Lutonix 035 Drug Coated Balloon Catheter
The objective of this patient registry is to assess the clinical use of the Lutonix 035 DCB PTA Catheter in a heterogeneous patient population in a real world and on-label clinical application.
- Conditions
- Peripheral Arterial Disease, Peripheral Vascular Diseases, Arterial Occlusive Diseases
- Trial name
- SAFE-DCB (NCT02424383)
- Testing
- PTA (Lutonix® 035 DCB Catheter)
- Where
- 73 sites in United States
- Volunteers
- 1,005 people
- Sponsor
- C. R. Bard
Peripheral Artery Disease
BRight DCB First-in-Human Study
The primary aim of this clinical study is to assess the safety and clinical performance of the BRight drug-coated balloon (DCB) in the treatment of lower limb arteries stenosis in subjects with Peripheral Artery Disease (PAD).
- Trial name
- NCT04525794
- Testing
- BRight DCB
- Where
- 7 sites in Australia, Austria and 2 more
- Volunteers
- 48 people
- Sponsor
- Biotronik CRC Inc.
Peripheral Arterial Disease
Safety Trial Of CTX Cells In Patients With Lower Limb Ischaemia
The primary objective of the Phase I ascending dose trial is to investigate the safety and tolerability of intramuscular (gastrocnemius) injections of human neural stem cell product, CTX, in patients with peripheral arterial…
- Trial name
- NCT01916369
- Testing
- CTX DP
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- ReNeuron Limited
Acute Coronary Syndrome
Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event
The purpose of this study is to determine the effect of VIA-2291 as compared to placebo on vascular inflammation following 24 weeks of dosing.
- Trial name
- NCT00552188
- Testing
- VIA-2291
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- Tallikut Pharmaceuticals, Inc.
Carotid Atherosclerosis, Peripheral Arterial Disease
Non-invasive Computer-Aided Phenotyping of Vasculopathy
The investigators use MRI and/or CT to evaluate the extent, as well as, the structure, composition, and functional aspects of atherosclerotic plaques in human carotid and femoral arteries in patients scheduled to undergo an…
- Trial name
- Q-CAMP (NCT02143102)
- Where
- 2 sites in United States
- Volunteers
- 125 people
- Sponsor
- Elucid Bioimaging Inc.
Peripheral Arterial Disease
Clinical Performance of the VESTO® Vascular Stent for Treatment of Iliac Peripheral Obstructive Arterial Disease
This study will validate the efficacy and safety of the VESTO® Vascular Stent for treating patients with iliac peripheral arterial obstructive disease in a post-market clinical trial
- Trial name
- VESTO-ILIAC (NCT06573437)
- Testing
- Vascular Stent - Vesto Endoprosthesis
- Where
- 6 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- Braile Biomedica Ind. Com. e Repr. Ltda.
Peripheral Artery Disease
Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon for Treatment of BTK Arteries
The study will enroll patients presenting with claudication, or critical limb ischemia (Rutherford Category 3- 5) and an angiographically significant (≥ 70%) native artery lesion appropriate for angioplasty that is below the…
- Trial name
- BTKRegistry (NCT02554266)
- Testing
- Lutonix 014 Drug Coated Balloon PTA Catheter
- Where
- 26 sites in Austria, Belgium and 9 more
- Volunteers
- 371 people
- Sponsor
- C. R. Bard
Atherosclerotic Lesions in the Aortorenal Ostium
A Prospective, Multi-center, Single Arm Study Evaluating the Express™ Renal Premounted Stent System in the Treatment of Atherosclerotic Lesions in the Aortorenal Ostium.
The purpose of this study is to demonstrate superior 9-month binary restenosis rate of the Express™ Renal Premounted Stent System as compared to an Objective Performance Criterion representative of PTRA, for atherosclerotic…
- Trial name
- RENAISSANCE (NCT00597142)
- Testing
- Express™ Renal Premounted Stent System
- Where
- 14 sites in United States
- Volunteers
- 100 people
- Sponsor
- Boston Scientific Corporation
Peripheral Vascular Disease
Trial to Evaluate the Safety & Efficacy of the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery
To determine the safety and efficacy of the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in subjects with atherosclerotic de novo or restenotic lesions in the native common iliac artery and/or native external iliac…
- Trial name
- MOBILITY OE (NCT01396525)
- Testing
- Omnilink Elite™ Peripheral Balloon-Expandable Stent System
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- Abbott Medical Devices
Peripheral Arterial Disease (PAD)
Safety Evaluation of Clopidogrel Sulfate in Patients With Peripheral Arterial Disease
Primary objective: To evaluate whether 12 weeks of clopidogrel is superior to ticlopidine in terms of lower risk of the safety events of interests in patients with peripheral arterial disease (PAD) Secondary objectives: To…
- Trial name
- NCT00862420
- Testing
- clopidogrel (SR25990), ticlopidine
- Where
- Japan
- Volunteers
- 431 people
- Sponsor
- Sanofi
Peripheral Arterial Disease, Peripheral Vascular Disease
Zilver® PTX™ Global Registry
The Zilver PTX Registry Study is a prospective, non-randomized, open-label, multicenter single-arm study enrolling patients in Europe, Asia, and North America with de novo or restenotic (including in-stent restenosis) lesions of…
- Trial name
- NCT01094678
- Testing
- Zilver® PTX™ Stent
- Where
- 4 sites in Germany, Italy
- Volunteers
- 788 people
- Sponsor
- Cook Group Incorporated
Atherosclerotic Cardiovascular Disease, Hypercholesterolemia
A Real-world Study of Inclisiran Adherence, Treatment Patterns, Patient Characteristics, and Effectiveness in ASCVD Patients With Hypercholesterolemia, ASCVD-risk Equivalent Patients With Hypercholesterolemia and Familial Hypercholesterolemia
This was a descriptive, non-interventional, retrospective cohort study among patients with atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia, ASCVD-risk equivalent (ASCVD-RE) or familial hypercholesterolemia…
- Trial name
- NCT06507852
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Novartis
Peripheral Arterial Disease
Advance® 18PTX® Balloon Catheter Study
The Advance® 18 PTX® Balloon Catheter study is a clinical trial to study the safety and effectiveness of the Advance 18® PTX® Balloon Catheter in the treatment of lesions in the superficial femoral artery and popliteal artery.
- Trial name
- NCT00776906
- Testing
- Advance® 18PTX® Balloon Catheter, Advance® 18LP Balloon Catheter
- Where
- 4 sites in Germany, Russia
- Volunteers
- 150 people
- Sponsor
- Cook Group Incorporated
Healthy Volunteers, Atherosclerotic Cardiovascular Disease
A Research Study Looking at How the Medicine NNC0385-0434 Works in the Body of Healthy Japanese Men
The aim of this study is to look at how the study medicine works in the body and how it is removed from the body. We are testing the study medicine to make a medicine that can help people lower their cholesterol level.
- Trial name
- NCT05003440
- Testing
- NNC0385-0434
- Where
- Japan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Cardiovascular Disease
Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study
Evaluate the effect of olpasiran administered subcutaneously (SC) compared with placebo, on percent change from baseline in lipoprotein(a) (Lp[a]).
- Trial name
- NCT04270760
- Testing
- Olpasiran
- Where
- 36 sites in United States, Australia and 5 more
- Volunteers
- 281 people
- Sponsor
- Amgen